Physiomics PLC Conference Attendance
07 Janeiro 2019 - 05:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
07 January 2019
Physiomics plc
("Physiomics") or ("the Company")
Conference attendance
Physiomics to participate in Biotech Showcase partnering
conference
Physiomics plc (AIM: PYC), is pleased to announce that it will
be attending the Biotech Showcase partnering conference in San
Francisco from 7-9 January 2019 during the JP Morgan Healthcare
Conference week. During this week, many of the world's most
successful biotech and pharmaceutical companies are present in San
Francisco to meet with prospective clients and partners. Over three
thousand attendees are expected to participate in over seven
thousand organised 1-1 meetings. Physiomics has confirmed meetings
with oncology companies from around the world interested in finding
out more about our Virtual Tumour platform and how it can enhance
their drug discovery and development programs.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a solutions provider to the R&D
based pharmaceutical and biotechnology industry with a focus on
oncology. The Company's Virtual Tumour technology uses computer
modelling to predict the effects of cancer drugs and treatments to
improve the success rate of drug discovery and development projects
while reducing time and cost. The predictive capability of Virtual
Tumour has been confirmed by over 60 projects, involving over 25
targets and 60 drugs, and has worked with clients such as Merck
KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
For more information please visit:
www.physiomics-plc.com
www.twitter.com/Physiomics
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAQZLFBKFFEBBQ
(END) Dow Jones Newswires
January 07, 2019 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024